Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Feb;98(5):e14382.
doi: 10.1097/MD.0000000000014382.

Spore Powder of Ganoderma Lucidum for Alzheimer's Disease: A Protocol for Systematic Review

Affiliations
Free PMC article

Spore Powder of Ganoderma Lucidum for Alzheimer's Disease: A Protocol for Systematic Review

Li-Hong Qin et al. Medicine (Baltimore). .
Free PMC article

Abstract

Background: Previous studies have reported that spore powder of Ganoderma lucidum (SPGL) may be effective for the treatment of Alzheimer's disease (AD). However, its efficacy is still inconclusive. Thus, this systematic review will aim to assess its efficacy and safety for AD.

Methods: We will search the electronic databases of Cochrane Central Register of Controlled Trials, EMBASE, MEDILINE, the Cumulative Index to Nursing and Allied Health Literature, Allied and Complementary Medicine Database, and Chinese Biomedical Literature Database to assess the efficacy and safety of SPGL for patients with AD from their inceptions to the present. All case-control studies and randomized controlled trials will be considered for inclusion in this study. Two review authors will independently perform the study selection, data extraction, and risk of bias evaluation.

Results: The primary outcome includes the cognitive status for patients. The secondary outcomes consist of the quality of life, AD symptoms, and adverse events.

Conclusions: This systematic review will present the existing evidence for the efficacy and safety of SPGL for treating patients with AD.

Dissemination and ethics: The results of this systematic review will be disseminated by through peer-reviewed journals. It does not needs ethic approval, because it does not involve individual patient data.

Systematic review registration: PROSPERO CRD42019119426.

Conflict of interest statement

The authors report no conflicts of interest.

Figures

Figure 1
Figure 1
Flowchart of study selection.

Similar articles

See all similar articles

Cited by 1 article

References

    1. Dos Santos Picanco LC, Ozela PF, de Fatima de Brito Brito M, et al. Alzheimer's disease: a review from the pathophysiology to diagnosis, new perspectives for pharmacological treatment. Curr Med Chem 2018;25:3141–59. - PubMed
    1. Nobis L, Husain M. Apathy in Alzheimer's disease. Curr Opin Behav Sci 2018;22:7–13. - PMC - PubMed
    1. Bondi MW, Edmonds EC, Salmon DP. Alzheimer's disease: past, present, and future. J Int Neuropsychol Soc 2017;23:818–31. - PMC - PubMed
    1. Loprinzi PD, Frith E, Ponce P. Memorcise and Alzheimer's disease. Phys Sportsmed 2018;46:145–54. - PubMed
    1. Ruthirakuhan MT, Herrmann N, Abraham EH, et al. Pharmacological interventions for apathy in Alzheimer's disease. Cochrane Database Syst Rev 2018;5:CD012197. - PMC - PubMed

Publication types

Feedback